期刊
VACCINE
卷 28, 期 19, 页码 3269-3272出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.02.098
关键词
Human papillomavirus; Oropharyngeal cancer; p16
资金
- Diagnostics and Technology Branch of the Australian Government Department of Health and Ageing
- Cure Cancer Foundation Australia and Sydney Head and Neck Cancer Institute
This study provides Australian data on the incidence of human papillomavirus(HPV)-related oropharyngeal cancer to aid the debate on extending the HPV vaccination programme to males The HPV status for 302 oropharyngeal cancers diagnosed between 1987 and 2006 was determined by HPV E6-targeted multiplex real-time PCR/p16 immunohistochemistry The overall HPV-positivity rate was 36% (94% types 16 and 18). HPV-related cancer increased from 19%(1987-1990) to 47%(2001-2005). HPV data used in conjunction with Australian cancer incidence data 2001-2005 showed that 1 56 cases of oropharyngeal cancer per 100.000 males per year were associated with HPV types targeted by the vaccine Vaccinating males may substantially reduce the burden of oropharyngeal cancer in Australia. (C) 2010 Elsevier Ltd All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据